Atorvia is early-stage biotech on a mission to end organ failure. With a key focus on proteomics, and assisted by machine learning tools, Atorvia is developing novel treatments targeting the regulated cell death pathway that causes organ failure.
Atorvia’s first therapeutic is at the lead identification stage with a first indication in kidney to prevent and treat Acute Kidney Injury – a common complication that occurs in tens of millions of patients each year and which currently lack treatment options. Many of these patients require dialysis and experience long-term health complications such as heart disease and diabetes – even from a single, temporary episode of kidney failure.
Atorvia is on a mission to end this.
Intellectual Property
Fundraising
Our website uses cookies to ensure you get the best experience. Learn more about the policy.
Are you developing and/or redesigning new green products, services, processes, and technologies that reduce environmental impact?
The i.d.e.a.™ Fund program focuses on supporting a more sustainable economy while fostering an inclusive and equitable growth in southern Ontario. Find out if you’re eligible to access up to $20,000 in matching seed funding and 30 hours of expert mentorship.
Applications are open from June 16 to July 7, 2025.
Since 2011, we’ve helped over 160 startups launch and scale their businesses. This fall, network with 350+ entrepreneurs, investors, and leaders at a milestone evening where community, growth & collaboration meet innovation.
Meet the top 10 finalists, and watch as they pitch their innovations live to a panel of investors and experts for cash prizes!
When: September 25, 2025 | 5:00pm – 9:00pm
Where: Oakville Banquet & Conference Centre |
2515 Wyecroft Rd, Oakville, ON L6L 6P8
